LEIPZIG INTERVENTIONAL COURSE

LINC 2024

Carotid Revascularization 2024:

Key Factors to Consider

Piotr Musialek

Jagiellonian University Dept. of Cardiac & Vascular Diseases
John Paul II Hospital, Kraków, Poland

Disclosure

Speaker name: Piotr Musialek
I have the following potential conflicts of interest to report:

☑ Consulting/Proctoring: Abbott Vascular, Balton, Gore, InspireMD, Medtronic

☐ Employment in industry

☐ Stockholder in a healthcare company

☐ Owner of a healthcare company

☑ Others: ESC Stroke Council Scientific Documents Task Force
Polish Cardiac Society Board Representative for Stroke and Vascular Interventions
CGUARDIANS FDA IDE Co-PI

Key Factors to Consider

- Whether?
- How?

Key Factors to Consider

- **Does ”this” Patient require carotid revasc. to ↓ Stroke Risk ?**

- **HOW to BEST revascularize ”this” Patient ?**

Cardiovasc Res. 2023 Aug 25:cvad135. doi: 10.1093/cvr/cvad135. Online ahead of print.

Stroke risk management in carotid atherosclerotic disease: A Clinical Consensus Statement of the ESC Council on Stroke and the ESC Working Group on Aorta and Peripheral Vascular Diseases

Piotr Musialek [1], Leo H Bonati [2], Richard Bulbulia [3 4], Alison Halliday [4], Birgit Bock [5], Laura Capoccia [6], Hans-Henning Eckstein [7], Iris Q Grunwald [8 9], Peck Lin Lip [10], Andre Monteiro [11], Kosmas I Paraskevas [12], Anna Podlasek [9 13], Barbara Rantner [14], Kenneth Rosenfield [15], Adnan H Siddiqui [16 17], Henrik Sillesen [18], Isabelle Van Herzeele [19], Tomasz J Guzik [20 21], Lucia Mazzolai [22], Victor Aboyans [23], Gregory Y H Lip [22]

ESC Stroke Council CONSENSUS Document

ESC



Thromb Haemost. 2022 Sep 28. doi: 10.1055/a-1952-1159. Online ahead of print.

Carotid Stenosis and Stroke: Medicines, Stents, Surgery – "Wait-and-See" or Protect?

Piotr Musialek [1], Kenneth Rosenfield [2], Adnan Siddiqui [3], Iris Q Grunwald [4]

LEIPZIG INTERVENTIONAL COURSE LINC 2024

Not a ”benign” condition…



The Journal of Cardiovascular Surgery 2024 mese;65(0):000–000
DOI:10.23736/S0021-9509.24.13093-5

LEIPZIG INTERVENTIONAL COURSE
LINC 2024

ORIGINAL ARTICLE

NOVEL DATA IN CAROTID-RELATED STROKE TREATMENT AND PREVENTION

Outcomes in acute carotid-related stroke eligible for mechanical reperfusion: SAFEGUARD-STROKE Registry

Lukasz TEKIELI [1, 2, 3] *, Karolina DZIERWA [4], Iris Q. GRUNWALD [5, 6], Adam MAZUREK [1, 2], Malgorzata URBANCZYK-ZAWADZKA [7], Lukasz WIEWIORKA [7], R. Pawel BANYS [7], Wladyslaw DABROWSKI [3], Anna PODLASEK [8, 9], Ewa WEGLARZ [3, 10], Justyna STEFANIAK [11], Rafal T. NIZANKOWSKI [12], Piotr MUSIALEK [1, 2]

[1]Stroke Thrombectomy-Capable Center, St. John Paul II Hospital, Krakow, Poland; [2]Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Krakow, Poland; [3]Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland; [4]Cardiovascular Imaging Laboratory, St. John Paul II Hospital, Krakow, Poland; [5]Division of Imaging Science and Technology, School of Medicine, University of Dundee, Dundee, UK; [6]Department of Radiology, University of Dundee Ninewells Hospital, Dundee, UK; [7]Department of Radiology, St. John Paul II Hospital, Krakow, Poland; [8]Tayside Innovation MedTech Ecosystem (TIME), University of Dundee, UK; [9]Precison Imaging Beacon, Radiological Sciences, University of Nottingham, Nottingham, UK; [10]Department of Nursing, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland; [11]Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, Krakow, Poland; [12]Accreditation Council, National Center for Health Quality Assessment, Krakow, Poland

*Corresponding author: Lukasz Tekieli, Department of Cardiac and Vascular Diseases, St. John Paul II Hospital, Ul. Pradnicla 80, 31-202 Krakow, Poland. E-mail: luk.tekieli@gmail.com



L. Tekieli, et al. *J Cardiovasc Surg* 2024 (in press)



L. Tekieli, et al. *J Cardiovasc Surg* 2024 (in press)



L. Tekieli, et al. *J Cardiovasc Surg* 2024 (in press)

LEIPZIG INTERVENTIONAL COURSE
LINC 2024

Carotid-Related STROKES

Should be Prevented

(rather than experienced…)

You can also **CAUSE Stroke**

while treating the carotid…

Decision-Making in Carotid Stenosis

Podlasek , Grunwald, Musiałek 2021

Decision-Making in Carotid Stenosis

TYPE OF INTERVENTION

(CAS, TCAR, CEA)

Podlasek , Grunwald, Musiałek 2021

Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data

Thomas G Brott, David Calvet*, George Howard, John Gregson, Ale Algra, Jean-Pierre Becquemin, Gert J de Borst, Richard Bulbulia, Hans-Henning Eckstein, Gustav Fraedrich, Jacoba P Greving, Alison Halliday, Jeroen Hendrikse, Olav Jansen, Jenifer H Voeks, Peter A Ringleb†, Jean-Louis Mas†, Martin M Brown†, Leo H Bonati†, on behalf of the Carotid Stenosis Trialists' Collaboration*



CREST-1

N Engl J Med 2010;363:11-23.

			Periprocedural Period		
	CAS (N=1262)	CEA (N=1240)	Absolute Treatment Effect of CAS vs. CEA (95% CI)	Hazard Ratio for CAS vs. CEA (95% CI)	P Value
	no. of patients (% ±SE)		*percentage points*		
Death	9 (0.7±0.2)	4 (0.3±0.2)	0.4 (–0.2 to 1.0)	2.25 (0.69 to 7.30)†	0.18†
Stroke					
Any	52 (4.1±0.6)	29 (2.3±0.4)	1.8 (0.4 to 3.2)	1.79 (1.14 to 2.82)	0.01
Major ipsilateral	11 (0.9±0.3)	4 (0.3±0.2)	0.5 (–0.1 to 1.2)	2.67 (0.85 to 8.40)	0.09
Major nonipsilateral‡	0	4 (0.3±0.2)	NA	NA	NA
Minor ipsilateral	37 (2.9±0.5)	17 (1.4±0.3)	1.6 (0.4 to 2.7)	2.16 (1.22 to 3.83)	0.009
Minor nonipsilateral	4 (0.3±0.2)	4 (0.3±0.2)	0.0 (–0.4 to 0.4)	1.02 (0.25 to 4.07)	0.98†
Myocardial infarction	14 (1.1±0.3)	28 (2.3±0.4)	–1.1 (–2.2 to –0.1)	0.50 (0.26 to 0.94)	0.03
Any periprocedural stroke or postprocedural ipsilateral stroke	52 (4.1±0.6)	29 (2.3±0.4)	1.8 (0.4 to 3.2)	1.79 (1.14 to 2.82)	0.01
Major stroke	11 (0.9±0.3)	8 (0.6±0.2)	0.2 (–0.5 to 0.9)	1.35 (0.54 to 3.36)	0.52
Minor stroke	41 (3.2±0.5)	21 (1.7±0.4)	1.6 (0.3 to 2.8)	1.95 (1.15 to 3.30)	0.01
Any periprocedural stroke or death or post-procedural ipsilateral stroke	55 (4.4±0.6)	29 (2.3±0.4)	2.0 (0.6 to 3.4)	1.90 (1.21 to 2.98)	0.005
Primary end point (any periprocedural stroke, myocardial infarction, or death or postprocedural ipsilateral stroke)	66 (5.2±0.6)	56 (4.5±0.6)	0.7 (–1.0 to 2.4)	1.18 (0.82 to 1.68)	0.38

LEIPZIG INTERVENTIONAL COURSE
LINC 2024

CREST-1

N Engl J Med 2010;363:11-23.

			Periprocedural Period		
	CAS (N=1262)	CEA (N=1240)	Absolute Treatment Effect of CAS vs. CEA (95% CI)	Hazard Ratio for CAS vs. CEA (95% CI)	P Value
	no. of patients (% ±SE)		*percentage points*		
Death	9 (0.7±0.2)	4 (0.3±0.2)	0.4 (–0.2 to 1.0)	2.25 (0.69 to 7.30)†	0.18†
Stroke					
Any	52 (4.1±0.6)	29 (2.3±0.4)	1.8 (0.4 to 3.2)	1.79 (1.14 to 2.82)	0.01
Major ipsilateral	11 (0.9±0.3)	4 (0.3±0.2)	0.5 (–0.1 to 1.2)	2.67 (0.85 to 8.40)	0.09
Major nonipsilateral‡	0	4 (0.3±0.2)	NA	NA	NA
Minor ipsilateral	37 (2.9±0.5)	17 (1.4±0.3)	1.6 (0.4 to 2.7)	2.16 (1.22 to 3.83)	0.009
Minor nonipsilateral	4 (0.3±0.2)	4 (0.3±0.2)	0.0 (–0.4 to 0.4)	1.02 (0.25 to 4.07)	0.98†
Myocardial infarction	4 (0.3±0.2)	7 (0.6±0.2)	–0.3 (–0.8 to 0.2)	0.57 (0.17 to 1.94)	0.03
Any periprocedural stroke or postprocedural ipsilateral stroke	52 (4.1±0.6)	29 (2.3±0.4)	1.8 (0.4 to 3.2)	1.79 (1.14 to 2.82)	0.01
Major stroke	11 (0.9±0.3)	8 (0.6±0.2)	0.2 (–0.5 to 0.9)	1.35 (0.54 to 3.36)	0.52
Minor stroke	41 (3.2±0.5)	21 (1.7±0.4)	1.6 (0.3 to 2.8)	1.95 (1.15 to 3.30)	0.01
Any periprocedural stroke or death or post-procedural ipsilateral stroke	55 (4.4±0.6)	29 (2.3±0.4)	2.0 (0.6 to 3.4)	1.90 (1.21 to 2.98)	0.005
Primary end point (any periprocedural stroke, myocardial infarction, or death or postprocedural ipsilateral stroke)	66 (5.2±0.6)	56 (4.5±0.6)	0.7 (–1.0 to 2.4)	1.18 (0.82 to 1.68)	0.38

WHERE exactly was the problem?

LEIPZIG INTERVENTIONAL COURSE
LINC 2024

The TIMING of Stroke by 30-days with CAS in CREST

- Day 0 — 29 → **50.0%**
- Day 1-7 — 10 → **17.2%**
- Day 8-30 — 19 → **32.8%**

The DAY AFTER to DAY 30

Hill MD. Circulation. 2012;126:3054–3061.

LEIPZIG INTERVENTIONAL COURSE LINC 2024

The TIMING of Stroke by 30-days with CAS in CAPTURE



* n= 168 patients; 2 patients each had two strokes

Fairman R. Ann Surg 2007;246:551–558.

CREST-1

N Engl J Med 2010;363:11-23.

LEIPZIG INTERVENTIONAL COURSE LINC 2024

	CAS (N=1262)	CEA (N=1240)	Periprocedural Period: Absolute Treatment Effect of CAS vs. CEA (95% CI)	Hazard Ratio for CAS vs. CEA (95% CI)	P Value
	no. of patients (% ±SE)		*percentage points*		
Death	9 (0.7±0.2)	4 (0.3±0.2)	0.4 (–0.2 to 1.0)	2.25 (0.69 to 7.30)†	0.18†
Stroke					
Any	52 (4.1±0.6)	29 (2.3±0.4)	1.8 (0.4 to 3.2)	1.79 (1.14 to 2.82)	0.01
Major ipsilateral	11 (0.9±0.3)	4 (0.3±0.2)	0.5 (–0.1 to 1.2)	2.67 (0.85 to 8.40)	0.09
Major nonipsilateral‡	0	4 (0.3±0.2)	NA	NA	NA
Minor ipsilateral	37 (2.9±0.5)	17 (1.4±0.3)	1.6 (0.4 to 2.7)	2.16 (1.22 to 3.83)	0.009
Minor nonipsilateral	4 (0.3±0.2)	4 (0.3±0.2)	0.0 (–0.4 to 0.4)	1.02 (0.25 to 4.07)	0.98†
Myocardial infarction	4 (0.3±0.2)	10 (0.8±0.3)	–0.5 (–1.2 to 0.1)	0.40 (0.12 to 1.34)	0.03
Any periprocedural stroke or postprocedural ipsilateral stroke	52 (4.1±0.6)	29 (2.3±0.4)	1.8 (0.4 to 3.2)	1.79 (1.14 to 2.82)	0.01
Major stroke	11 (0.9±0.3)	8 (0.6±0.2)	0.2 (–0.5 to 0.9)	1.35 (0.54 to 3.36)	0.52
Minor stroke	41 (3.2±0.5)	21 (1.7±0.4)	1.6 (0.3 to 2.8)	1.95 (1.15 to 3.30)	0.01
Any periprocedural stroke or death or post-procedural ipsilateral stroke	55 (4.4±0.6)	29 (2.3±0.4)	2.0 (0.6 to 3.4)	1.90 (1.21 to 2.98)	0.005
Primary end point (any periprocedural stroke, myocardial infarction, or death or postprocedural ipsilateral stroke)	66 (5.2±0.6)	56 (4.5±0.6)	0.7 (–1.0 to 2.4)	1.18 (0.82 to 1.68)	0.38

WHERE exactly was the problem?

The Problem of Conventional (Single-layer) Carotid Stents



P Musialek, G deDonato
Carotid Artery Revascularization Using the Endovascular Route
In: **Carotid Interventions - Practical Guide 2023**

Mechanisms to explain the poor results of carotid artery stenting (CAS) in symptomatic patients to date and options to improve CAS outcomes

Kosmas I. Paraskevas, MD,[a] Dimitri P. Mikhailidis, MD, FFPM, FRCPath, FRCP,[b] and Frank J. Veith, MD, FACS,[c,d] *Athens, Greece; London, United Kingdom; Cleveland, Ohio; and New York, NY*

Background: Carotid artery stenting (CAS) is considered by many as an alternative to carotid endarterectomy (CEA) for the management of carotid artery stenosis. However, recent trials demonstrated inferior results for CAS in symptomatic patients compared with CEA. We reviewed the literature to evaluate the appropriateness of CAS for symptomatic carotid artery stenosis and to determine the pathogenetic mechanism(s) associated with stroke following the treatment of such lesions. Based on this, we propose steps to improve the results of CAS for the treatment of symptomatic carotid stenosis.
Methods: PubMed/Medline was searched up to March 25, 2010 for studies investigating the efficacy of CAS for the management of symptomatic carotid stenosis. Search terms used were "carotid artery stenting," "symptomatic carotid artery stenosis," "carotid endarterectomy," "stroke," "recurrent carotid stenosis," and "long-term results" in various combinations.
Results: Current data suggest that CAS is not equivalent to CEA for the treatment of symptomatic carotid stenosis. Differences in carotid plaque morphology and a higher incidence of microemboli and cerebrovascular events during and after CAS compared with CEA may account for these inferior results.
Conclusions: Currently, most symptomatic patients are inappropriate candidates for CAS. Improved CAS technology referable to stent design and embolic protection strategies may alter this conclusion in the future. (J Vasc Surg 2010;52: 1367-75.)

Carotid 'mesh' stents: 2nd Gen Carotid Stents

Gore Hybrid Stent



Casper/RoadSaver

CGuard

P Musialek, G deDonato
Carotid Artery Revascularization Using the Endovascular Route
In: **Carotid Interventions - Practical Guide 2023**

Carotid 'mesh' stents

			
Name	**RoadSaver *aka* Casper**	**Gore® Carotid Stent**	**CGuard™ Embolic Prevention Stent**
Stent frame	closed-cell Nitinol	open-cell Nitinol	open-cell Nitinol
Mesh position in relation to frame	inside	outside	outside
Mesh material	Nitinol	PTFE	PET
Mesh structure	braided	inter-woven	single-fiber knitted
Pore size	375 µm	500 µm	150 - 180 µm

Clinical Investigation

JOURNAL OF ENDOVASCULAR THERAPY

Journal of Endovascular Therapy
2015, Vol. 22(4) 634–639

DOI: 10.1177/1526602815593490
www.jevt.org
SAGE

Mechanical Behavior of a New Double-Layer Carotid Stent

Christian Wissgott, MD[1], Wolfram Schmidt, BSE[2], Christoph Brandt, BSE[2], Peter Behrens, BSE[2], and Reimer Andresen, MD[1]





Clinical Investigation

JOURNAL OF ENDOVASCULAR THERAPY

Journal of Endovascular Therapy
1–8

DOI: 10.1177/1526602816671134
www.jevt.org
SAGE

Clinical Results and Mechanical Properties of the Carotid CGUARD Double-Layered Embolic Prevention Stent







The **MOST 'open'** amongst open-cell stents (metallic FRAME) & the **MOST 'close'** amongst close-cell stents (MicroNet mesh)

CGuard MicroNET – covered
2nd generation carotid stent

UNIQUE mechanical properties

RESPECT of anatomy

FULL apposition



NORMAL healing



LEIPZIG INTERVENTIONAL COURSE
LINC 2024

Randomized Controlled Trial

The CREST Study stent



MicroNet-Covered Stent

OCT Images in: P Musialek, G deDonato
Carotid Artery Revascularization Using the Endovascular Route
In: **Carotid Interventions - Practical Guide 2022** (in press)

Neuro-Protective
Carotid Stent System

Randomized Controlled Trial

DW-MRI Embolism
raw data



JACC: CARDIOVASCULAR INTERVENTIONS VOL. 14, NO. 21, 2021
NOVEMBER 8, 2021:2377-2387



Level 1 Evidence

Embolic Load to the Brain
PROFOUND REDUCTION
Acculink (CREST study device)

MicroNet-Covered Stent - CGuard



Blinded CoreLab independent anaysis

CGuard
MicroNET-Covered Stent

New Technologies
P Musialek @ LINC 2024

2nd Gen Carotid Stents ('mesh' stents)

- significantly reduce the **incidence** of embolic material in filters
- significantly reduce **filter load**
- profoundly reduce CAS-related **cerebral injury**

Karpenko A. *JACC Cardiovasc Interv* 2021;14:2377–87.
Nakagawa I. *J Neurointerv Surg* 2023;16:67–72.
Squizzato F. *Stroke* 2023;54:2534–41.

2nd Gen Carotid Stents ('mesh' stents)

Clinical Data

Randomized Controlled Trial of Conventional Versus MicroNet-Covered Stent in Carotid Artery Revascularization

12-month clinical data



JACC: CARDIOVASCULAR INTERVENTIONS VOL. 16, NO. 7, 2023

Systematic Review

Clinical Outcomes of Second- versus First-Generation Carotid Stents: A Systematic Review and Meta-Analysis

Adam Mazurek [1,*], Krzysztof Malinowski [2], Kenneth Rosenfield [3], Laura Capoccia [4], Francesco Speziale [4], Gianmarco de Donato [5], Carlo Setacci [5], Christian Wissgott [6], Pasqualino Sirignano [4], Lukasz Tekieli [7], Andrey Karpenko [8], Waclaw Kuczmik [9], Eugenio Stabile [10], David Christopher Metzger [11], Max Amor [12], Adnan H. Siddiqui [13], Antonio Micari [14], Piotr Pieniążek [1,7], Alberto Cremonesi [15], Joachim Schofer [16], Andrej Schmidt [17] and Piotr Musialek [1,*,†] on behalf of CARMEN (CArotid Revascularization Systematic Reviews and MEta-aNalyses) Investigators

Data of **68,422** patients

from **112 eligible studies**

(68.2% men, 44.9% symptomatic)

CARMEN Systematic review and meta-analysis flowchart (PRISMA)



J. Clin. Med. **2022**, *11*, 4819. https://doi.org/10.3390/jcm11164819

CARMEN SGS vs FGS Meta-Analysis: Main Findings

A **30-day Stroke**

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 26	100%	0.20 [0.08–0.32]
Casper/RoadSaver	585 5	23.1%	0.17 [0.02–0.31]
Gore Mesh Stent	311 9	12.3%	0.96 [0.75–1.17]
CGuard MicroNET Stent	1635 12	64.6%	0.18 [0.06–0.30]

Heterogeneity: I^2=87%, τ^2=0.0003, p<0.01



B **30-day Death/Stroke/MI**

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 44	100%	0.32 [0.17–0.46]
Casper/RoadSaver	585 10	23.1%	0.33 [0.14–0.51]
Gore Mesh Stent	311 15	12.3%	1.17 [0.94–1.41]
CGuard MicroNET Stent	1635 19	64.6%	0.26 [0.12–0.40]

Heterogeneity: I^2=87%, τ^2=0.0004, p<0.01



CARMEN SGS vs FGS Meta-Analysis: Main Findings

A 30-day Stroke

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 26	100%	0.20 [0.08–0.32]
Casper/RoadSaver	585 5	23.1%	0.17 [0.02–0.31]
Gore Mesh Stent	311 9	12.3%	0.96 [0.75–1.17]
CGuard MicroNET Stent	1635 12	64.6%	0.18 [0.06–0.30]

Heterogeneity: I^2=87%, τ^2=0.0003, p<0.01



B 30-day Death/Stroke/MI

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 44	100%	0.32 [0.17–0.46]
Casper/RoadSaver	585 10	23.1%	0.33 [0.14–0.51]
Gore Mesh Stent	311 15	12.3%	1.17 [0.94–1.41]
CGuard MicroNET Stent	1635 19	64.6%	0.26 [0.12–0.40]

Heterogeneity: I^2=87%, τ^2=0.0004, p<0.01



C 12-month Ipsilateral Stroke

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	1191 15	100%	0.20 [0.02–0.39]
Casper/RoadSaver	348 3	29.2%	0.07 [0.00–0.27]
Gore Mesh Stent	290 9	24.4%	0.88 [0.64–1.13]
CGuard MicroNET Stent	553 3	46.4%	0.11 [0.00–0.28]

Heterogeneity: I^2=86%, τ^2=0.0002, p<0.01



D 12-month Restenosis

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	1191 42	100%	0.85 [0.60–1.10]
Casper/RoadSaver	348 26	29.2%	1.80 [1.53–2.08]
Gore Mesh Stent	290 14	24.4%	1.22 [0.95–1.48]
CGuard MicroNET Stent	553 2	46.4%	0.09 [0.00–0.26]

Heterogeneity: I^2=88%, τ^2=0.0003, p<0.01



LEIPZIG INTERVENTIONAL COURSE
LINC 2024

CARMEN SGS vs FGS Meta-Analysis: Main Findings

Open-cell FGS as reference

A 30-day Stroke

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 26	100%	0.19 [0.06–0.33]
Casper/RoadSaver	585 5	23.1%	0.16 [0.00–0.32]
Gore Mesh Stent	311 9	12.3%	0.92 [0.70–1.14]
CGuard MicroNET Stent	1635 12	64.6%	0.17 [0.03–0.31]

Heterogeneity: I^2=83%, τ^2=0.0002, p<0.01



B 30-day Death/Stroke/MI

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 44	100%	0.31 [0.14–0.48]
Casper/RoadSaver	585 10	23.1%	0.32 [0.11–0.52]
Gore Mesh Stent	311 15	12.3%	1.15 [0.91–1.40]
CGuard MicroNET Stent	1635 19	64.6%	0.26 [0.10–0.42]

Heterogeneity: I^2=84%, τ^2=0.0003, p<0.01



Close-cell FGS as reference

C 30-day Stroke

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 26	100%	0.26 [0.11–0.41]
Casper/RoadSaver	585 5	23.1%	0.21 [0.04–0.38]
Gore Mesh Stent	311 9	12.3%	1.25 [1.02–1.48]
CGuard MicroNET Stent	1635 12	64.6%	0.23 [0.08–0.39]

Heterogeneity: I^2=72%, τ^2=0.0001, p<0.01



D 30-day Death/Stroke/MI

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 44	100%	0.41 [0.23–0.59]
Casper/RoadSaver	585 10	23.1%	0.42 [0.21–0.63]
Gore Mesh Stent	311 15	12.3%	1.53 [1.28–1.79]
CGuard MicroNET Stent	1635 19	64.6%	0.34 [0.17–0.51]

Heterogeneity: I^2=73%, τ^2=0.0002, p<0.01



Systematic Review

Clinical Outcomes of Second- versus First-Generation Carotid Stents: A Systematic Review and Meta-Analysis

Adam Mazurek [1,*], Krzysztof Malinowski [2], Kenneth Rosenfield [3], Laura Capoccia [4], Francesco Speziale [4], Gianmarco de Donato [5], Carlo Setacci [5], Christian Wissgott [6], Pasqualino Sirignano [4], Lukasz Tekieli [7], Andrey Karpenko [8], Waclaw Kuczmik [9], Eugenio Stabile [10], David Christopher Metzger [11], Max Amor [12], Adnan H. Siddiqui [13], Antonio Micari [14], Piotr Pieniążek [1,7], Alberto Cremonesi [15], Joachim Schofer [16], Andrej Schmidt [17] and Piotr Musialek [1,*,†] on behalf of CARMEN (CArotid Revascularization Systematic Reviews and MEta-aNalyses) Investigators

Conclusions: Pooled SGS use was associated with improved short- and long-term clinical results of CAS. Individual SGS types, however, differed significantly in their outcomes, indicating a lack of a "mesh stent" class effect. **Findings from this meta-analysis may provide clinically relevant information** (…).

103,642 Patients

The Journal of Cardiovascular Surgery 2023 December;64(6):570-82
DOI: 10.23736/S0021-9509.24.12933-3

LATEST TECHNIQUES FOR CAROTID REVASCULARIZATION

Carotid artery revascularization using second generation stents *versus* surgery: a meta-analysis of clinical outcomes

Adam MAZUREK [1, 2] *, Krzysztof MALINOWSKI [3, 4], Pasqualino SIRIGNANO [5], Ralf KOLVENBACH [6], Laura CAPOCCIA [7], Gianmarco DE DONATO [8], Isabelle VAN HERZEELE [9], Adnan H. SIDDIQUI [10, 11], Tomaso CASTRUCCI [12], Lukasz TEKIELI [1, 2, 13], Matteo STEFANINI [14], Christian WISSGOTT [15], Kenneth ROSENFIELD [16], D. Christopher METZGER [17], Kenneth SNYDER [18], Andrey KARPENKO [19], Waclaw KUCZMIK [20], Eugenio STABILE [21], Magdalena KNAPIK [22], Renato CASANA [23], Piotr PIENIAZEK [1, 13], Anna PODLASEK [24, 25], Maurizio TAURINO [5], Joachim SCHOFER [26], Alberto CREMONESI [27, 28], Horst SIEVERT [29], Andrej SCHMIDT [30], Iris Q. GRUNWALD [24, 31], Francesco SPEZIALE [7], Carlo SETACCI [8], Piotr MUSIALEK [1, 2], CArotid Revascularization systematic reviews and MEta-aNalyses (CARMEN) Collaborators

(PROSPERO-CRD42022339789)

SGS vs CEA meta-analysis



1. **CEA** pooled data

SAPPHIRE
EVA 3S
SPACE-1
ICSS
CREST
ACST-1
ACT-1
Manhaim
SPACE-2

CARMEN Collaborators
J Cardiovasc Surg 2023

SGS vs CEA meta-analysis

Major
RCTs
Involving CEA

1. **CEA** pooled data

SAPPHIRE
EVA 3S
SPACE-1
ICSS
CREST
ACST-1
ACT-1
Manhaim
SPACE-2

CEA in
Contemporary
Clinical Practice

2. **CEA** in Vascular Quality Initiative (**VQI**) database*

* Dakour-Aridi H, et al. *Ann Vasc Surg.* 2020;65:1-9
Columbo JA, et al. *J Vasc Surg.* 2019;69:104-109

CARMEN Collaborators
J Cardiovasc Surg 2023

30-day Stroke

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 26	100%	0.24 [0.10–0.38]
Casper/RoadSaver	585 5	23.1%	0.20 [0.04–0.36]
Gore Mesh Stent	311 9	12.3%	1.15 [0.92–1.37]
CGuard MicroNET Stent	1635 12	64.6%	0.22 [0.07–0.36]

Heterogeneity: I^2=71%, τ^2<0.0001, p<0.01



Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	2531 26	100%	0.53 [0.44–0.62]
Casper/RoadSaver	585 5	23.1%	0.44 [0.32–0.56]
Gore Mesh Stent	311 9	12.3%	2.55 [2.35–2.75]
CGuard MicroNET Stent	1635 12	64.6%	0.48 [0.39–0.57]

Heterogeneity: I^2=40%, τ^2<0.0001, p=0.06



CARMEN Collaborators
J Cardiovasc Surg 2023

12-month Restenosis

Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	1191 42	100%	1.30 [1.05−1.55]
Casper/RoadSaver	348 26	29.2%	2.75 [2.48−3.02]
Gore Mesh Stent	290 14	24.4%	0.94 [0.80−1.08]
CGuard MicroNET Stent	553 2	46.4%	0.16 [0.08−0.24]

Heterogeneity: I^2=84%, τ^2=0.0002, p<0.01



Study	Patients Events	Weight	Risk Ratio [95% CI]
SGS	1191 42	100%	1.45 [1.25−1.65]
Casper/RoadSaver	348 26	29.2%	3.08 [2.84−3.32]
Gore Mesh Stent	290 14	24.4%	2.08 [1.85−2.31]
CGuard MicroNET Stent	553 2	46.4%	0.14 [0.04−0.24]

Heterogeneity: I^2=93%, τ^2=0.0002, p<0.01



CARMEN Collaborators
J Cardiovasc Surg 2023

The Journal of Cardiovascular Surgery 2023 December;64(6):570-82
DOI: 10.23736/S0021-9509.24.12933-3

LATEST TECHNIQUES FOR CAROTID REVASCULARIZATION

Carotid artery revascularization using second generation stents *versus* surgery: a meta-analysis of clinical outcomes

Meta-analytic integration of available clinical data indicates:

1) reduction in stroke but increased restenosis rate with Casper/Roadsaver,
2) reduction in both stroke and restenosis with CGuard MicroNET-covered stent

against contemporary CEA outcomes at 30 days and 12 months used as reference.

New Technologies

FDA-IDE Clinical Trial:

CGUARDIANS

NCT 04900844

InspireMD

C-GUARDIANS Study Design	Prospective, multicenter, single- armed IDE Pivotal trial
Sample size/ Sites	316 Patients; 25 US and European Sites
Primary Endpoint	***Composite of death, stroke, MI (DSMI) at 30 days*** or ipsilateral stroke at 1 year
Sponsor	INSPIRE MD
Principal Investigator **Co- Principal Investigator**	D. Chris Metzger, MD Piotr Musialek, MD
Study Enrollment Period	July, 2021 to June, 2023 (23 months)
Monitor/ CRO	Hart Clinical Consultants

Patient Demographics

Characteristic	ITT (N = 316)
Age (mean ± SD)	69.0 ± 6.6
% Symptomatic	24.3%
% Male	63.9%
Diabetes Mellitus	41.8%
Hypertension	92.6%
Dyslipidemia	90%
CAD	52.1%
COPD	23.8%
Current Smoker	26.4%
PVD	28.6%

D Chris Metzger @ VIVA 2023

Embolic Protection Utilized

Emboshield NAV 6 Distal embolic protection	**261**
MoMA Proximal embolic protection	78
Both (Nav6 and MoMa)	24
None	1

D Chris Metzger @ VIVA 2023

C-GUARDIANS 30-day Results

ITT Analysis (N = 316)	Event rate in % (n)
Death, Stroke or MI*	0.95%(3)
Death#	0.32% (1)
Any stroke#	0.95% (3)
Major Stroke#	0.63% (2)
Minor Stroke#	0.32% (1)
MI	0.0% (0)
Death or any stroke*	0.95% (3)
Death or major stroke*	0.63% (2)

D Chris Metzger @ VIVA 2023

* Hierarchical: patient count (each patient first occurrence of the most serious event).

Non-hierarchical: event count (multiple events in each patient are counted individually).

New Technologies

P Musialek @ LINC 2024

CGUARDIANS FDA-IDE CAS vs. ACST-2 CEA

30-day STROKE	0.95% vs. 2.4%
30-day Death/Stroke/MI	0.95% vs. 3.2%

p=0.029

Metzger DC. (on behalf of CGUARDIANSFDA-IDE Trial Investigators). 30-Day Results From the C-Guardians Pivotal Trial of the CGuard Carotid Stent System. https://vivafoundation.org/
Halliday A, et al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. Lancet 2021;398:1065–73.

Cardiovasc Res. 2023 Aug 25:cvad135. doi: 10.1093/cvr/cvad135. Online ahead of print.

Stroke risk management in carotid atherosclerotic disease: A Clinical Consensus Statement of the ESC Council on Stroke and the ESC Working Group on Aorta and Peripheral Vascular Diseases

Piotr Musialek [1], Leo H Bonati [2], Richard Bulbulia [3 4], Alison Halliday [4], Birgit Bock [5], Laura Capoccia [6], Hans-Henning Eckstein [7], Iris Q Grunwald [8 9], Peck Lin Lip [10], Andre Monteiro [11], Kosmas I Paraskevas [12], Anna Podlasek [9 13], Barbara Rantner [14], Kenneth Rosenfield [15], Adnan H Siddiqui [16 17], Henrik Sillesen [18], Isabelle Van Herzeele [19], Tomasz J Guzik [20 21], Lucia Mazzolai [22], Victor Aboyans [23], Gregory Y H Lip [22]

ESC Stroke Council CONSENSUS Document

ESC



LEIPZIG INTERVENTIONAL COURSE
LINC 2024

The Journal of Cardiovascular Surgery 2023 December;64(6):555-60
DOI: 10.23736/S0021-9509.23.12956-9

LATEST TECHNIQUES FOR CAROTID REVASCULARIZATION

Carotid stent as cerebral protector: the arrival of Godot

Piotr MUSIALEK [1, 2] *, Ralf LANGHOFF [3], Matteo STEFANINI [4], William A. GRAY [5, 6, 7]

[1]Department of Cardiac and Vascular Diseases, Jagiellonian University, Krakow, Poland; [2]St. John Paul II Hospital, Stroke Thrombectomy-Capable Center, Krakow, Poland; [3]Department of Angiology, Sankt-Gertrauden Hospital, Academic Teaching Hospital of Charité University, Berlin, Germany; [4]Department of Radiology and Interventional Radiology, Casilino Hospital, Rome, Italy; [5]Main Line Health, Wynnewood, PA, USA; [6]Sidney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA, USA; [7]Lankenau Heart Institute, Wynnewood, PA, USA

*Corresponding author: Piotr Musialek, Department of Cardiac and Vascular Diseases, Jagiellonian University, St. John Paul II Hospital, ul. Pradnicka 80, 31-202 Krakow, Poland. E-mail: pmusialek@szpitaljp2.krakow.pl

With respect to clinical decision-making, it is important to understand that any historic data (such as data obtained using prior-generation devices that were unable to effectively isolate the atherosclerotic lesion material) need to be viewed as having, today, a mostly historical value.

Mechanisms to explain the poor results of carotid artery stenting (CAS) in symptomatic patients to date and options to improve CAS outcomes

Kosmas I. Paraskevas, MD,[a] Dimitri P. Mikhailidis, MD, FFPM, FRCPath, FRCP,[b] and Frank J. Veith, MD, FACS,[c,d] *Athens, Greece; London, United Kingdom; Cleveland, Ohio; and New York, NY*

Background: Carotid artery stenting (CAS) is considered by many as an alternative to carotid endarterectomy (CEA) for the management of carotid artery stenosis. However, recent trials demonstrated inferior results for CAS in symptomatic patients compared with CEA. We reviewed the literature to evaluate the appropriateness of CAS for symptomatic carotid artery stenosis and to determine the pathogenetic mechanism(s) associated with stroke following the treatment of such lesions. Based on this, we propose steps to improve the results of CAS for the treatment of symptomatic carotid stenosis.
Methods: PubMed/Medline was searched up to March 25, 2010 for studies investigating the efficacy of CAS for the management of symptomatic carotid stenosis. Search terms used were "carotid artery stenting," "symptomatic carotid artery stenosis," "carotid endarterectomy," "stroke," "recurrent carotid stenosis," and "long-term results" in various combinations.
Results: Current data suggest that CAS is not equivalent to CEA for the treatment of symptomatic carotid stenosis. Differences in carotid plaque morphology and a higher incidence of microemboli and cerebrovascular events during and after CAS compared with CEA may account for these inferior results.
Conclusions: Currently, most symptomatic patients are inappropriate candidates for CAS. Improved CAS technology referable to stent design and embolic protection strategies may alter this conclusion in the future. (J Vasc Surg 2010;52: 1367-75.)

Cardiovasc Res. 2023 Aug 25:cvad135. doi: 10.1093/cvr/cvad135. Online ahead of print.

Stroke risk management in carotid atherosclerotic disease: A Clinical Consensus Statement of the ESC Council on Stroke and the ESC Working Group on Aorta and Peripheral Vascular Diseases

Piotr Musialek [1], Leo H Bonati [2], Richard Bulbulia [3 4], Alison Halliday [4], Birgit Bock [5], Laura Capoccia [6], Hans-Henning Eckstein [7], Iris Q Grunwald [8 9], Peck Lin Lip [10], Andre Monteiro [11], Kosmas I Paraskevas [12], Anna Podlasek [9 13], Barbara Rantner [14], Kenneth Rosenfield [15], Adnan H Siddiqui [16 17], Henrik Sillesen [18], Isabelle Van Herzeele [19], Tomasz J Guzik [20 21], Lucia Mazzolai [22], Victor Aboyans [23], Gregory Y H Lip [22]

ESC Stroke Council CONSENSUS Document

ESC



LEIPZIG INTERVENTIONAL COURSE
LINC 2024

Key Factors to Consider

- **Does ”this” Patient require carotid revasc. to ↓ Stroke Risk ?**

- **HOW to BEST revascularize ”this” Patient ?**

Key Factors to Consider

- **Does ”this” Patient require carotid revasc. to ↓ Stroke Risk ?**
  - **Plaque Characteristics**
  - **Family risk of Stroke?**
  - **Others (eg. Diabetes as a strong risk-modifying factor)**
- **HOW to BEST revascularize ”this” Patient ?**

Key Factors to Consider

- **Does ”this” Patient require carotid revasc. to ↓ Stroke Risk ?**
  - Plaque Characteristics
  - Family risk of Stroke?
  - Others (eg. Diabetes as a strong risk-modifying factor)
- **HOW to BEST revascularize ”this” Patient ?**
  - **Overall CONTEMPORARY CAS vs. CEA Data**
  - **Center Experience**
  - **Operator Expertise**

Key Factors to Consider

- **Does ”this” Patient require carotid revasc. to ↓ Stroke Risk ?**
  - **Plaque Characteristics**
  - **Family risk of Stroke?**
  - **Others (eg. Diabetes as a strong risk-modifying factor)**
- **HOW to BEST revascularize ”this” Patient ?**
  - **Overall CONTEMPORARY CAS vs. CEA Data**
  - **Center Experience**
  - **Operator Expertise**

Key Factors to Consider

CEA 'Technical' Issues

Key Factors to Consider

CEA **'Technical' Issues**

CAS **'Technical' Issues**

Key Factors to Consider

CEA 'Technical' Issues

CAS 'Technical' Issues

Key Factors to Consider

CEA 'Technical' Issues

CAS 'Technical' Issues

- Lesion severity?
- GA vs Local anaesthesia?
- Completion study (Duplex/Angio)?

Misclassification of carotid stenosis severity with area stenosis-based evaluation by computed tomography angiography: impact on erroneous indication to revascularization or patient (lesion) migration to a higher guideline recommendation class as per ESC/ESVS/ESO/SVS and CMS-FDA thresholds

Adv Interv Cardiol 2022; 18, 4 (70): 500–513
DOI: https://doi.org/10.5114/aic.2023.125610



Stenosis severity based decision-making in symptomatic lesions

ESC/ESVS/ESO/SVS*/CMS-FDA thresholds



Misclassification of carotid stenosis severity with area stenosis-based evaluation by computed tomography angiography: impact on erroneous indication to revascularization or patient (lesion) migration to a higher guideline recommendation class as per ESC/ESVS/ESO/SVS and CMS-FDA thresholds



Figure 4. Effect of replacing – in asymptomatic lesions – cQA diameter stenosis-based measurement of carotid "% stenosis" (reference standard) with CTA-derived area stenosis calculation on lesion (patient) migration to another guideline category.

Adv Interv Cardiol 2022; 18, 4 (70): 500–513
DOI: https://doi.org/10.5114/aic.2023.125610

Key Factors to Consider

CEA 'Technical' Issues

- Lesion severity?
- GA vs Local anaesthesia?
- Completion study (Duplex/Angio)?

CAS 'Technical' Issues

- Neuroprotection Type (Prox vs Dist)?
- Stent Type (Anti-Embolic)
- Stent Post-dilatation/Optimization

Key Factors to Consider

CEA 'Technical' Issues

- Lesion severity?
- GA vs Local anaesthesia?
- Completion study (Duplex/Angio)?

CAS 'Technical' Issues

- Neuroprotection Type (Prox vs Dist)?
- Stent Type (Anti-Embolic)
- Stent Post-dilatation/Optimization

In conclusion,

The landscape has changed

Improving carotid artery stenting to match carotid endarterectomy: a task accomplished

Piotr Musialek[1,2]*, MD, DPhil; Kosmas I. Paraskevas[3], MD, PhD; Gary S. Roubin[4], MD, PhD

*Corresponding author: Department of Cardiac & Vascular Diseases, Jagiellonian University, Stroke Thrombectomy-Capable Centre, St. John Paul II Hospital, ul. Pradnicka 80, 31-202, Krakow, Poland. E-mail: pmusialek@szpitaljp2.krakow.pl

There are no scientific reasons today that the carotid artery should remain the last artery in the body "reserved" for preferential open surgery. Today, physicians, and more importantly patients[2], do have a choice of treatment mode.

EuroIntervention
2024;20:e402-e404


JP2 Krakow Team
P. Pieniazek
P. Paluszek
L. Tekieli
E. Weglarz
A. Mazurek
GUARDIANS
FDA
INSPIREMD
EUROPE
#1
KRAKOW, POLAND
APRIL 12, 2022

LEIPZIG INTERVENTIONAL COURSE

LINC 2024

CAS with Proximal Protection:

How to **OPTIMIZE** Your Outcomes?

Piotr Musialek

Jagiellonian University Dept. of Cardiac & Vascular Diseases
John Paul II Hospital, Kraków, Poland